JP2018519802A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018519802A5 JP2018519802A5 JP2017560132A JP2017560132A JP2018519802A5 JP 2018519802 A5 JP2018519802 A5 JP 2018519802A5 JP 2017560132 A JP2017560132 A JP 2017560132A JP 2017560132 A JP2017560132 A JP 2017560132A JP 2018519802 A5 JP2018519802 A5 JP 2018519802A5
- Authority
- JP
- Japan
- Prior art keywords
- mutein
- nucleotide sequence
- nucleic acid
- encoded
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021127923A JP7217783B2 (ja) | 2015-05-18 | 2021-08-04 | グリピカン－３（ｇｐｃ３）に対する親和性を有するヒトリポカリン２のムテイン |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15167922 | 2015-05-18 | ||
| EP15167922.2 | 2015-05-18 | ||
| PCT/EP2016/061058 WO2016184875A1 (en) | 2015-05-18 | 2016-05-18 | Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021127923A Division JP7217783B2 (ja) | 2015-05-18 | 2021-08-04 | グリピカン－３（ｇｐｃ３）に対する親和性を有するヒトリポカリン２のムテイン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018519802A JP2018519802A (ja) | 2018-07-26 |
| JP2018519802A5 true JP2018519802A5 (enExample) | 2019-06-20 |
| JP6942060B2 JP6942060B2 (ja) | 2021-09-29 |
Family
ID=53180583
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017560132A Expired - Fee Related JP6942060B2 (ja) | 2015-05-18 | 2016-05-18 | グリピカン−３（ｇｐｃ３）に対する親和性を有するヒトリポカリン２のムテイン |
| JP2021127923A Active JP7217783B2 (ja) | 2015-05-18 | 2021-08-04 | グリピカン－３（ｇｐｃ３）に対する親和性を有するヒトリポカリン２のムテイン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021127923A Active JP7217783B2 (ja) | 2015-05-18 | 2021-08-04 | グリピカン－３（ｇｐｃ３）に対する親和性を有するヒトリポカリン２のムテイン |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10273275B2 (enExample) |
| EP (1) | EP3298029A1 (enExample) |
| JP (2) | JP6942060B2 (enExample) |
| KR (1) | KR20180008649A (enExample) |
| CN (2) | CN107787327B (enExample) |
| AU (1) | AU2016262838B2 (enExample) |
| BR (1) | BR112017020961A2 (enExample) |
| CA (1) | CA2982034A1 (enExample) |
| MX (1) | MX2017014730A (enExample) |
| RU (1) | RU2756318C2 (enExample) |
| SG (1) | SG11201707872WA (enExample) |
| WO (1) | WO2016184875A1 (enExample) |
| ZA (1) | ZA201706605B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012013662B1 (pt) | 2009-12-07 | 2022-08-02 | Pieris Pharmaceuticals Gmbh | Muteínas de lipocalina associada à gelatinase de neutrófilo humano (lcn2, hngal), seu uso e seus métodos de geração e produção, molécula de ácido nucleico, célula hospedeira, composição farmacêutica e kit de diagnóstico ou analítico |
| EP2920202B1 (en) | 2012-11-19 | 2018-08-29 | Pieris Pharmaceuticals GmbH | Novel specific-binding polypeptides and uses thereof |
| EP3145945B1 (en) | 2014-05-22 | 2020-07-15 | Pieris Pharmaceuticals GmbH | Novel specific-binding polypeptides and uses thereof |
| SG11201705278QA (en) | 2015-01-28 | 2017-07-28 | Pieris Pharmaceuticals Gmbh | Novel proteins specific for angiogenesis |
| PH12017501583B1 (en) | 2015-05-04 | 2023-01-20 | Pieris Pharmaceuticals Gmbh | Novel proteins specific for cd137 |
| RU2727165C2 (ru) | 2015-05-04 | 2020-07-21 | ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ | Слитый полипептид с противораковой активностью |
| DK3298030T5 (en) | 2015-05-18 | 2024-10-07 | Pieris Pharmaceuticals Gmbh | Anti-cancerfusionspolypeptid |
| EP3298029A1 (en) | 2015-05-18 | 2018-03-28 | Pieris Pharmaceuticals GmbH | Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3) |
| EP3115371A1 (en) | 2015-07-07 | 2017-01-11 | Sanofi | Fusion molecules |
| US10703810B2 (en) | 2015-11-30 | 2020-07-07 | Pieris Australia Pty Ltd. | Fusion polypeptides which bind vascular endothelial growth factor a (VEGF-A) and angiopoietin-2 (Ang-2) |
| TW201725212A (zh) | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
| JP7476219B2 (ja) | 2019-02-26 | 2024-04-30 | ピエリス ファーマシューティカルズ ゲーエムベーハー | Ｃｄ１３７およびｇｐｃ３に特異的な新規融合タンパク質 |
| CN113939307A (zh) | 2019-03-29 | 2022-01-14 | 皮里斯制药有限公司 | 脂质运载蛋白突变蛋白的吸入施用 |
| CA3177098A1 (en) | 2020-06-05 | 2021-12-09 | Pieris Pharmaceuticals Gmbh | Multimeric immunomodulator targeting 4-1bb |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2032831T5 (es) | 1986-08-19 | 2001-02-16 | Genentech Inc | Dispositivo y dispersion para suministro intrapulmonar de factores de crecimiento polipeptidos y citoquinas. |
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| AU696387B2 (en) | 1994-05-18 | 1998-09-10 | Inhale Therapeutic Systems, Inc. | Methods and compositions for the dry powder formulation of interferons |
| DE4417598A1 (de) | 1994-05-19 | 1995-12-14 | Max Planck Gesellschaft | Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen |
| WO1996023879A1 (en) | 1995-01-30 | 1996-08-08 | Terrapin Technologies, Inc. | Glubodies - multiplicities of proteins capable of binding a variety of small molecules |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| DE19641876B4 (de) | 1996-10-10 | 2011-09-29 | Iba Gmbh | Streptavidinmuteine |
| WO1998016873A1 (en) | 1996-10-14 | 1998-04-23 | Firm Forsat Ltd. | Method for preparing dispersions of chromogenic components |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| JP3839667B2 (ja) | 1998-06-08 | 2006-11-01 | エフ．ホフマン−ラ ロシュ アーゲー | 慢性Ｃ型肝炎の処置のためのＰｅｇ−ＩＮＦ−アルファ及びリバビリンの使用 |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| AU2001294617A1 (en) | 2000-09-21 | 2002-04-02 | University Of Massachusetts | Method of inducing apoptosis in lymphoid cells |
| US7211395B2 (en) | 2001-03-09 | 2007-05-01 | Dyax Corp. | Serum albumin binding moieties |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| US7118915B2 (en) | 2001-09-27 | 2006-10-10 | Pieris Proteolab Ag | Muteins of apolipoprotein D |
| US7691970B2 (en) | 2003-08-25 | 2010-04-06 | Pieris Ag | Muteins of a bilin-binding protein with affinity for a given target |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| JP2007284351A (ja) | 2004-07-27 | 2007-11-01 | Osaka Bioscience Institute | アミロイド蛋白質の凝集を抑制する物質とその作用 |
| US7892827B2 (en) | 2004-11-26 | 2011-02-22 | Pieris Ag | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| JP5299942B2 (ja) * | 2005-08-09 | 2013-09-25 | オンコセラピー・サイエンス株式会社 | ＨＬＡ−Ａ２陽性者用ｇｌｙｐｉｃａｎ−３（ＧＰＣ３）由来癌拒絶抗原ペプチド及びこれを含む医薬 |
| AU2006294644A1 (en) | 2005-09-27 | 2007-04-05 | Amunix, Inc. | Proteinaceous pharmaceuticals and uses thereof |
| US20070087005A1 (en) | 2005-10-14 | 2007-04-19 | Lazar Gregory A | Anti-glypican-3 antibody |
| EP1996613B1 (en) * | 2006-03-20 | 2014-04-30 | Technische Universität München | Muteins of tear lipocalin with affinity for the t-cell coreceptor cd4 |
| WO2007137170A2 (en) | 2006-05-20 | 2007-11-29 | Seattle Genetics, Inc. | Anti-glypican-3 antibody drug conjugates |
| DE602007009995D1 (de) | 2006-08-01 | 2010-12-02 | Pieris Ag | Muteine von tearlipocalin und verfahren zu deren gewinnung |
| AU2008275985B2 (en) | 2007-07-17 | 2013-09-19 | E. R. Squibb & Sons, L.L.C. | Monoclonal antibodies against Glypican-3 |
| EP2225268B1 (en) | 2007-10-19 | 2012-08-29 | Abbott Laboratories | Immunoassays and kits for the detection of ngal |
| US8420051B2 (en) | 2008-06-24 | 2013-04-16 | Technische Universitaet Meunchen | Muteins of hNGAL and related proteins with affinity for a given target |
| BR112012013662B1 (pt) * | 2009-12-07 | 2022-08-02 | Pieris Pharmaceuticals Gmbh | Muteínas de lipocalina associada à gelatinase de neutrófilo humano (lcn2, hngal), seu uso e seus métodos de geração e produção, molécula de ácido nucleico, célula hospedeira, composição farmacêutica e kit de diagnóstico ou analítico |
| JP2013529907A (ja) | 2010-05-24 | 2013-07-25 | ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク | Ｎｇａｌタンパク質変異体及びその使用 |
| AU2011263786B2 (en) | 2010-06-08 | 2014-11-13 | Astrazeneca Ab | Tear lipocalin muteins binding IL-4 R alpha |
| AU2011290751B2 (en) | 2010-08-16 | 2015-08-13 | Pieris Ag | Binding proteins for Hepcidin |
| CA2817779C (en) * | 2010-11-15 | 2019-02-19 | Pieris Pharmaceuticals Gmbh | Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3) |
| US20130225505A1 (en) | 2011-11-23 | 2013-08-29 | Allergan, Inc. | Muteins of human tear lipcalin for treating neovascular disease of the anterior segment of the human eye |
| WO2013174783A1 (en) * | 2012-05-23 | 2013-11-28 | Pieris Ag | Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3 |
| EP2920202B1 (en) * | 2012-11-19 | 2018-08-29 | Pieris Pharmaceuticals GmbH | Novel specific-binding polypeptides and uses thereof |
| SG11201705278QA (en) | 2015-01-28 | 2017-07-28 | Pieris Pharmaceuticals Gmbh | Novel proteins specific for angiogenesis |
| EP3259282A1 (en) | 2015-02-18 | 2017-12-27 | Sanofi | Novel proteins specific for pyoverdine and pyochelin |
| PH12017501583B1 (en) | 2015-05-04 | 2023-01-20 | Pieris Pharmaceuticals Gmbh | Novel proteins specific for cd137 |
| EP3298029A1 (en) | 2015-05-18 | 2018-03-28 | Pieris Pharmaceuticals GmbH | Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3) |
-
2016
- 2016-05-18 EP EP16729194.7A patent/EP3298029A1/en not_active Withdrawn
- 2016-05-18 JP JP2017560132A patent/JP6942060B2/ja not_active Expired - Fee Related
- 2016-05-18 SG SG11201707872WA patent/SG11201707872WA/en unknown
- 2016-05-18 KR KR1020177036061A patent/KR20180008649A/ko not_active Ceased
- 2016-05-18 CN CN201680028942.8A patent/CN107787327B/zh not_active Expired - Fee Related
- 2016-05-18 RU RU2017135605A patent/RU2756318C2/ru active
- 2016-05-18 US US15/575,271 patent/US10273275B2/en active Active
- 2016-05-18 BR BR112017020961-6A patent/BR112017020961A2/pt not_active Application Discontinuation
- 2016-05-18 MX MX2017014730A patent/MX2017014730A/es unknown
- 2016-05-18 WO PCT/EP2016/061058 patent/WO2016184875A1/en not_active Ceased
- 2016-05-18 CN CN202210050736.4A patent/CN114456252A/zh active Pending
- 2016-05-18 AU AU2016262838A patent/AU2016262838B2/en not_active Ceased
- 2016-05-18 CA CA2982034A patent/CA2982034A1/en active Pending
-
2017
- 2017-10-02 ZA ZA2017/06605A patent/ZA201706605B/en unknown
-
2019
- 2019-04-19 US US16/389,115 patent/US10787491B2/en not_active Expired - Fee Related
-
2021
- 2021-08-04 JP JP2021127923A patent/JP7217783B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018532372A5 (enExample) | ||
| JP2018515084A5 (enExample) | ||
| JP2014502149A5 (enExample) | ||
| RU2016149596A (ru) | Новые полипептиды со специфическим связыванием и пути их применения | |
| CN109641046B (zh) | 单链可变片段cd3结合蛋白质 | |
| JP2017518748A5 (enExample) | ||
| CN110437320B (zh) | 多肽 | |
| JP2021006024A5 (enExample) | ||
| JP2019506140A5 (enExample) | ||
| JP2020505948A5 (enExample) | ||
| TWI436776B (zh) | Ｆｇｆ２１突變體及其用途 | |
| US10233238B2 (en) | TNF alpha antibody or fragment thereof and methods of use | |
| JP2013512683A5 (enExample) | ||
| RU2015137158A (ru) | МУТЕИНЫ ЛИПОКАЛИНА 2 ЧЕЛОВЕКА (Lcn2,hNGAL) С АФФИННОСТЬЮ ДЛЯ ОПРЕДЕЛЕННОЙ МИШЕНИ | |
| JP2018526989A5 (enExample) | ||
| RU2019122482A (ru) | Мутеины липокалина с аффинностью связывания в отношении lag-3 | |
| RU2017128105A (ru) | Новые белки, специфические в отношении ангиогенеза | |
| JP2017527272A5 (enExample) | ||
| JP2018509887A5 (enExample) | ||
| CN114539411B (zh) | 一种ror1抗体或其抗原结合片段 | |
| JP2018519803A5 (enExample) | ||
| AU2014314222B2 (en) | Stable polypeptides binding to human complement C5 | |
| JP2016519051A5 (enExample) | ||
| KR20150058454A (ko) | 알부민 결합 폴리펩타이드 | |
| RU2017135605A (ru) | Мутеины липокалина 2 человека с аффинностью в отношении глипикана-3 (gpc3) |